| 1 |
Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers[J]. Curr Top Microbiol Immunol,2010 ,347 :21-41.
|
| 2 |
Jacinto E, Loewith R, Schmidt A,et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive[J]. Nat Cell Biol,2004,6: 1122-1128.
|
| 3 |
Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation[J]. Exp Cell Res, 1999 ,25 : 100-109.
|
| 4 |
Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy[J]. Expert Opin Ther Targets, 2012,16(1):121-130.
|
| 5 |
Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease[J]. Nat Genet,2005,37:19-24.
|
| 6 |
Cozzone D, Fröjdö S, Disse E, et al. Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients[J]. Diabetologia,2008,51 (3):512-521.
|
| 7 |
Adjei AA, Hidal M. Intracellular signal transduction pathway proteins as targets for cancer therapy [J]. J Clin Oncol, 2005, 23 : 5386-5403.
|
| 8 |
Canto C, Jiang L Q, Deshmukh AS,et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle[J]. Cell Metab,2010,11(3) :213-219.
|
| 9 |
Kim SA, Choi HC. Metformin inhibits inflammatory response via AMPK-PTEN? pathway in vascular smooth muscle cells [J]. Biochem Biophys Res Commun,2012,425(4) :866-872.
|
| 10 |
Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/ PTEN/AKT/mTOR and Jak/STAT pathways to leukemia[J]. Leukemia,2008,22(4) : 686-707.
|
| 11 |
Carter BZ, Milella M, Altieri DC, el al. Cytokine-regulated expression of survivin in myeloid leukemia[J], Blood,2001,97 (9): 2784-2790.
|
| 12 |
Guo Q, Li Y. Research on the expression of Survivin and PTEN in laryngeal squamous cell carcinoma transplanted on the back sides of nude mice treated by gold throat tablets[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,2012,26(24) : 1134-1137.
|
| 13 |
Yan J, Zhou H, Kong L,et al. Identification of two novel inhibitors of mTOR signaling pathway based on high content screening[J]. Cancer Chemother Pharmacol.,2013,23 (10) : 123-127.
|
| 14 |
Choe G, Horvath S, Clouqhesy TF, et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathyway in glioblastoma patients in vivo[J]. Cancer Res,2003,63(12) : 2742-2746.
|
| 15 |
Neve RM, Horvath S, Hynes NE. Distinct roles for phosphoinostide 3-kinase,mitogen-activated protein kinase and P38 MAPK in mediating cell cycle progression of breast cancer cells[J]. Oncoqene,2002,21:4567-4576.
|
| 16 |
Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors[J]. Cancer Res,2001,61 : 7426-7429.
|
| 17 |
Welker ME, Kulik G. Recent syntheses ofPI3K/Akt/mTOR signaling pathway inhibitors[J]. Bioorg Med Chem, 2013 ,21(14): 4063-4091.
|
| 18 |
Korets SB, Czok S, Blank SV. Targeting the mTOR/4E-BP pathway in endometrial cancer[J]. Clin Cancer Res, 2011,17(24): 7518-7528.
|
| 19 |
Pratheeshkumar P, Budhraja A. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways[J]. PLoS One, 2012,7(10):331-336.
|
| 20 |
Cantley LC, Neel BG. New insights into tumor suppression:PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway[J]. Proc Natl Acad Sci USA, 1999, 96 (8): 4240-4245.
|
| 21 |
Chen X, Wang Y, Luo H. β-elemene acts as an antitumor factor and down regulates the expression of survivin, Bcl-xL and Mta-1 [J]. Mol Med Rep,2012,6(5) :989-995.
|
| 22 |
Heselmeyer K, Schrock E, du Manoir S,et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix[J]. Proc Natl Acad Sci USA, 1996,93(1) :479-484.
|
| 23 |
Shayesteh L, LuY, Kuo WL, et al. PIK3CA is implicated as oncogene in ovarian cancer[J]. Nat Genet,1999,21 (1): 99-102.
|
| 24 |
Ji J, Gu TT, Zheng PS. The expression and clinical significanceof mTOR/ P70S6K signaling pathway in cervical cancer [J]. J Xi'an Jiaotong Univ:Med Sci,2010,31(1) : 10-13.
|
| 25 |
Chen YJ, Liu J, Tao YJ, et al. Expression of PTEN, PI3K, mTOR in nasopharyngeal carcinoma and their significance[J]. Mod Oncol, 2009,17(1):41-43.
|
| 26 |
Nathan CO, Amirghahari N, Rong X, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer [J]. Cancer Res,2007,67(5) :2160-2168.
|
| 27 |
Xia BR, Meng FL, Lu BY. The expression and clinical significance of mTOR,Eie4e,4E-BP1 in cervical cancer [J]. Pract Oncol J, 2011,25(4):301-305.
|
| 28 |
Rizvi MM, Alam MS, Ali A,et al. Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population[J]. J Cancer Res Clin Oncol,2011,137(8) : 1255-1262.
|
| 29 |
Lu D, Qian J, Yin X, et al. Expression of PTEN and survivin in cervical cancer:Promising biological markers for early diagnosis and prognostic evaluation[J]. Br J Biomed Sci,2012,69(4) : 143-146.
|
| 30 |
Wen ZF, Fan HJ, Zhang HJ. The expression and significance of p-PKB and PTEN in cervical cancer [J]. Med Inform, 2011, 24 (2): 961-963.
|
| 31 |
Zhu H, Shi ZZ, Yang XJ, et al. The Expression and clinical significance of survivin,Bcl-2 and HPV16/18 in cervical intraepithelial neoplasia and cervical cancer[J]. J Pract Obstet Gynecol,2010,26(1) :57-60.
|
| 32 |
Yu J, Wang DH. The expression of survivin and PTEN in cervical cancer and associated research [J]. J Tianjin Med Univ, 2011, 17 (2):240-242.
|